TinyGemsBreaks Archive - Page 95 of 128

WednesdayNov 16, 2022 4:50 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds Four New Client Locations, Continues Impressive Growth Expansion

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), announced the deployment of its proprietary ASRs to four new locations. The new agreement represents the growing reach and versatility that Knightscope offers as it works to protect individuals, property and possessions across an array of different verticals. One new ASR will be providing key surveillance at a leading U.S.-based operator of casinos and gaming facilities with more than three dozen casino locations; this is the second K5 ASR activated by this client and the first Knightscope ASR deployment in the state of Iowa. A second K1 ASR was…

WednesdayNov 16, 2022 4:34 pm

TinyGemsBreaks – Tingo Inc. (TMNA), MICT Inc. (NASDAQ: MICT) Announce Tingo Mobile PLC’s Launch of Key Partnerships

Tingo (OTC: TMNA) and MICT (NASDAQ: MICT) today announced that Tingo Mobile, which is being wholly acquired by MICT with a scheduled completion date of Nov. 30, 2022, has launched its partnership with the All Farmers Association of Nigeria (“AFAN”) ahead of schedule. Through its recently disclosed trade deal with Tingo Mobile, AFAN has committed to deliver a minimum of 20 million additional subscribers, which would more than triple Tingo Mobile’s existing customer base of 9.3 million. Tingo Mobile also launched its pan-African partnership with leading global payments technology company, Visa, with the rollout a range of new products and…

WednesdayNov 16, 2022 2:52 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Featured in Chardan Report, Receives ‘Buy’ Rating

Freight Technologies (NASDAQ: FRGT), a technology company based on its custom-developed Fr8App platform, which is powered by AI and machine learning and which offers a real-time portal for B2B cross-border shipping and domestic shipping within the United States-Mexico-Canada (“NAFTA”) region, was featured in a recent Chardan report. Chardan is an independent, full-service, global investment bank. The Chardan report is the first analyst coverage that Freight Technologies has received since going public, and the report concludes with a “buy” recommendation. The rating “validates what we have been trying to message all along,” the announcement stated, reaffirming the company’s focus on offering…

WednesdayNov 16, 2022 2:36 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Marks Key Step in Progress Toward Commercializing Medicinal Cannabis

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced the completion of its new laboratory located in Bogota, Colombia. Specializing in the manufacturing of compound formulations utilizing cannabis derivatives and traditional master formulas, Flora Lab 4 will become part of Flora’s group of laboratories. These include existing labs that produce cosmetics, phytotherapeutic products, dietary supplements, and cannabis extraction and transformation. “The completion of Flora Lab 4 is an important step in Flora Growth’s progress toward commercializing medicinal cannabis. This lab is built to produce prescription-grade medications and manufacture cannabis-based formulations,” said…

WednesdayNov 16, 2022 2:09 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Featured in New Report Discussing Growth in EV Space

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is grabbing attention in the competitive electric vehicle space. A leading investor resource covering EV stocks, Investor Ideas recently released a special news report about the growth in the EV sector, which featured Mullen, mentioning the company’s Strikingly Different EV Crossover Tour, which features the Mullen FIVE EV Crossover. The report quoted social media EV influencer Joe Fay, who attended the tour and said, “I'm completely blown away by the design, craftsmanship, and quality of the FIVE and can't wait to get this vehicle out in front of my fans.” In…

WednesdayNov 16, 2022 1:56 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

TuesdayNov 15, 2022 2:18 pm

TinyGemsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) ‘Strikingly Different’ EV Crossover Tour Takes the Spotlight in Vegas, Heads to Texas

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has successfully completed the third stop of the Mullen FIVE Strikingly Different EV Crossover Tour in Las Vegas, Nevada. According to the announcement, Mullen continues onwards to Texas, with stops this week in Dallas and Houston. The Mullen FIVE EV vehicle on tour is equipped with a completely updated infotainment system that features PERSONA, Mullen’s proprietary Personal Vehicle Assistant (“PVA”), which utilizes facial recognition technology to provide every driver with a highly individualized experience. “This tour not only allows the public to see what Mullen has…

TuesdayNov 15, 2022 1:53 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early for formal conclusions to be made of these results, CycloSam generally performed how we expected it to perform, even given the lowest dosage in our dose-escalating study. This is all very encouraging,” said Douglas R.…

TuesdayNov 15, 2022 1:23 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent…

TuesdayNov 15, 2022 11:51 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced its Q3 2022 financial report; the company also provided an update regarding its anticancer drug candidates. The report noted that significant progress has been made in CNSP’s key trial designed to study Berubicin’s efficacy in the treatment of recurrent glioblastoma multiforme (“GBM”); that progress includes multiple clinical trial sites being approved for enrollment along with 29 of 68 clinical sites in the United States and Europe already enrolling patients. The company anticipates…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks